Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Vericel Corporation (VCEL)
Vericel Corporation (VCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,258,347
  • Shares Outstanding, K 47,725
  • Annual Sales, $ 164,370 K
  • Annual Income, $ -16,710 K
  • 60-Month Beta 1.70
  • Price/Sales 12.13
  • Price/Cash Flow N/A
  • Price/Book 11.22
Trade VCEL with:

Options Overview Details

View History
  • Implied Volatility 56.01% ( +3.91%)
  • Historical Volatility 39.80%
  • IV Percentile 51%
  • IV Rank 58.94%
  • IV High 73.49% on 03/14/23
  • IV Low 30.91% on 12/27/23
  • Put/Call Vol Ratio 2.50
  • Today's Volume 14
  • Volume Avg (30-Day) 131
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 2,536
  • Open Int (30-Day) 2,010

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.18
  • Number of Estimates 4
  • High Estimate 0.20
  • Low Estimate 0.16
  • Prior Year 0.12
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.78 +16.04%
on 01/24/24
50.09 -5.53%
on 02/20/24
+5.07 (+12.00%)
since 01/23/24
3-Month
32.31 +46.46%
on 01/08/24
50.09 -5.53%
on 02/20/24
+11.83 (+33.33%)
since 11/22/23
52-Week
27.92 +69.48%
on 03/10/23
50.09 -5.53%
on 02/20/24
+16.72 (+54.64%)
since 02/23/23

Most Recent Stories

More News
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -23.08% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

VCEL : 47.32 (-2.05%)
PRQR : 2.04 (+0.49%)
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 1.19% and 19.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

RPTX : 6.34 (+1.28%)
VCEL : 47.32 (-2.05%)
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 2.75% and 6.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TWST : 38.20 (-1.09%)
VCEL : 47.32 (-2.05%)
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 28.93% and 3.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 157.65 (-3.17%)
VCEL : 47.32 (-2.05%)
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

/PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments...

SGTX : 22.47 (-2.56%)
ATRS : 5.59 (unch)
VCEL : 47.32 (-2.05%)
Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains?

Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

ALLO : 4.54 (+4.13%)
VCEL : 47.32 (-2.05%)
Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VCEL : 47.32 (-2.05%)
LQDA : 14.32 (+1.99%)
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

VCEL : 47.32 (-2.05%)
ABUS : 2.92 (+0.34%)
Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

Kytopen , an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to...

VCEL : 47.32 (-2.05%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 47.32 (-2.05%)
OCEL : 2.6150 (-18.03%)
BRTX : 1.3700 (+4.58%)
MDXG : 8.20 (+0.24%)
NNVC : 1.3300 (+4.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

3rd Resistance Point 49.62
2nd Resistance Point 49.11
1st Resistance Point 48.22
Last Price 47.32
1st Support Level 46.81
2nd Support Level 46.30
3rd Support Level 45.41

See More

52-Week High 50.09
Last Price 47.32
Fibonacci 61.8% 41.62
Fibonacci 50% 39.01
Fibonacci 38.2% 36.39
52-Week Low 27.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar